Gedeon Richter Provides Clues On Key Biosimilar Trial Dates
Denosumab And Tocilizumab In Richter’s Pipeline
Hungary’s Gedeon Richter achieved record results in 2020, driven by a near trebling of the firm’s group operating profit and rising sales. Management once again had much to say on the company’s biosimilar ambitions.
You may also be interested in...
Hungary’s Gedeon Richter is continuing to divert the greatest proportion of its R&D cash to biosimilars. Management updated on its pipeline and broader group prospects amid Russia’s military invasion of Ukraine.
Hikma has made the next move to build up its nascent US biosimilars business by striking a deal with Gedeon Richter for its denosumab candidate.
Teva has officially confirmed one of its many biosimilar assets is a rival to Amgen’s Prolia (denosumab) to treat osteoporosis in postmenopausal women. Sandoz, Celltrion and Samsung Bioepis are among those that have previously thrown their hats into the ring.